Weiss Ratings Reaffirms "Sell (D)" Rating for Keros Therapeutics (NASDAQ:KROS)

Key Points

• Weiss Ratings has reiterated a "sell (D)" rating for Keros Therapeutics (NASDAQ: KROS) in a recent report.
• Recent analyst activity includes HC Wainwright reducing their price target from $25.00 to $20.00 while maintaining a "buy" rating, and Bank of America downgrading the stock from "buy" to "neutral" with a price target cut from $32.00 to $18.00.
• Keros Therapeutics reported a significant year-over-year revenue increase of 49,002.7%, although it posted a quarterly loss of ($0.76) EPS compared to a consensus estimate of ($1.14).

Keros Therapeutics (NASDAQ:KROS - Get Free Report)'s stock had its "sell (d)" rating reiterated by equities researchers at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Several other equities research analysts have also recently weighed in on the stock. HC Wainwright decreased their price objective on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Bank of America cut shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and cut their price target for the company from $32.00 to $18.00 in a research report on Tuesday, June 10th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $30.00.

Keros Therapeutics Price Performance

Shares of KROS opened at $15.96 on Wednesday. The business has a 50-day moving average of $15.17 and a 200-day moving average of $14.02. The company has a market capitalization of $648.30 million, a price-to-earnings ratio of 51.49, a price-to-earnings-growth ratio of 2.02 and a beta of 0.97. Keros Therapeutics has a 1 year low of $9.12 and a 1 year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The business had revenue of $0.02 million for the quarter, compared to analysts' expectations of $3.83 million. During the same period in the prior year, the business posted ($1.25) earnings per share. The firm's revenue was up 49002.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors have recently made changes to their positions in the stock. FNY Investment Advisers LLC bought a new position in shares of Keros Therapeutics during the 1st quarter worth about $25,000. CWM LLC boosted its holdings in Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company's stock worth $27,000 after acquiring an additional 2,641 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock valued at $42,000 after acquiring an additional 1,888 shares during the period. Police & Firemen s Retirement System of New Jersey grew its stake in Keros Therapeutics by 29.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company's stock valued at $110,000 after acquiring an additional 1,892 shares during the period. Finally, Entropy Technologies LP bought a new stake in shares of Keros Therapeutics during the first quarter valued at approximately $121,000. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.